Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at PLN 555.2B, ahead of Pfizer (PLN 491.2B) and Johnson & Johnson (PLN 476.2B). Figures as of 20 Nov 2026, 02:03 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbViePLN 555.2B
- Median
- PLN 3.4B
- Combined market value
- PLN 15.12T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | PLN 555.2B | PLN 2.03T | PLN 1,147.43 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | PLN 491.2B | PLN 635.2B | PLN 111.45 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | PLN 476.2B | PLN 2.6T | PLN 1,081.06 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | PLN 347.8B | PLN 4.87T | PLN 5,467.71 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | PLN 340.8B | PLN 1.32T | PLN 537.46 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | PLN 289.5B | PLN 482.6B | PLN 236.09 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | PLN 137.4B | PLN 728B | PLN 420.34 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | PLN 91B | PLN 92.2B | PLN 80.45 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | PLN 49.1B | PLN 132.8B | PLN 326.94 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | PLN 40.1B | PLN 157.6B | PLN 274.05 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | PLN 37.6B | PLN 386.5B | PLN 3,736.57 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | PLN 28.2B | PLN 534.2B | PLN 2,107.01 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | PLN 27.6B | PLN 53.2B | PLN 106.39 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | PLN 16.9B | PLN 80.1B | PLN 598.20 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | PLN 14.9B | PLN 30.2B | PLN 86.56 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | PLN 12.6B | PLN 19.7B | PLN 236.03 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | PLN 12.3B | PLN 18.3B | PLN 110.15 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | PLN 12.2B | PLN 61.6B | PLN 316.38 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | PLN 8.4B | PLN 29B | PLN 208.25 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | PLN 6.2B | PLN 128.2B | PLN 584.60 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | PLN 6.1B | PLN 48.1B | PLN 248.55 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | PLN 3.6B | PLN 25B | PLN 176.64 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | PLN 3.2B | PLN 96.4B | PLN 2,262.57 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | PLN 3B | PLN 12.6B | PLN 65.15 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | PLN 2.7B | PLN 37.3B | PLN 1,605.53 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | PLN 2.4B | PLN 28.9B | PLN 549.07 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | PLN 2.2B | PLN 23.2B | PLN 1,161.19 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | PLN 2.1B | PLN 25.2B | PLN 386.51 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | PLN 2B | PLN 18.8B | PLN 195.46 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | PLN 1.7B | PLN 39.7B | PLN 262.56 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | PLN 1.2B | PLN 19.5B | PLN 112.26 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | PLN 850.5M | PLN 32.8B | PLN 472.67 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | PLN 764.2M | PLN 28.8B | PLN 262.96 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | PLN 436.1M | PLN 16.3B | PLN 119.30 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | PLN 373.6M | PLN 34.2B | PLN 42.77 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | PLN 287.3M | PLN 20.2B | PLN 57.55 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | PLN 253.1M | PLN 37.5B | PLN 395.09 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | PLN 241.9M | PLN 35.2B | PLN 1,258.15 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | PLN 216.4M | PLN 32.8B | PLN 501.88 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | PLN 151.8M | PLN 19.3B | PLN 343.29 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | PLN 122.8M | PLN 18.2B | PLN 166.61 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | PLN 67.5M | PLN 26.8B | PLN 394.85 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | PLN 40.8M | PLN 24.8B | PLN 611.15 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | PLN 37.1M | PLN 21.2B | PLN 503.38 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0468 PLN).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (PLN 555.2B), Pfizer (PLN 491.2B) and Johnson & Johnson (PLN 476.2B) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 02:03 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of PLN 15.12T as of 20 Nov 2026, 02:03 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.